The mosquito-borne virus has emerged as a global threat, with a new vaccine evaluated in two large clinical trials in North America. The new shot is a single-dose injection to the muscle.
A new strategy to test investigational treatments for patients with OA is about to begin in patients who are at risk for accelerated development of OA following ACL reconstructive surgery.
Mirikizumab (Omvoh) is the first IL-23 inhibitor to be approved in the United States for the treament of moderately to severely active ulcerative colitis.